Search for: "Pharmaceutical Product Development, Inc." Results 1 - 20 of 1,240
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
The FTC Office of Patent Invalidation
6 May 2024, 8:26 am by Daniel J. Gilman
We don’t want to impugn good patents or heap undue costs on firms that develop useful pharmaceuticals. [read post]
Truth on the Market - http://truthonthemarket.com/
Regeneron Accused of Drug Pricing Fraud in Latest FCA Case
24 Apr 2024, 4:52 am by Erica Blachman Hitchings
According to a recent press release, the Department of Justice has filed a Complaint against New York-based Regeneron Pharmaceuticals Inc. [read post]
Whistleblower Blog and News - https://www.whistleblowerllc.com/blog-news/
Federal Income Taxation of Intellectual Property Development and Cost Recovery
9 Apr 2024, 2:56 pm by Brian Clark
Proc. 97-35, and cases like RJR Nabisco, Inc. v. [read post]
Dollars & Sense - https://dollarsandsense.grayreed.com/
FTC’s Campaign Against Improper Orange Book Listings Continues with Amicus Brief in Teva’s Challenge of Amneal Asthma Inhaler ANDA
3 Apr 2024, 1:07 pm by Bevin Newman
The Federal Trade Commission (“FTC”) has filed an amicus brief in Teva Branded Pharmaceuticals Products R&D, Inc. v. [read post]
Antitrust Law Blog - http://www.antitrustlawblog.com/
Obviousness and Pharmaceutical Method of Treatment Claims
1 Apr 2024, 10:58 am by Dennis Crouch
Janssen Pharms., Inc. v. [read post]
Patently-O - https://patentlyo.com
Federal Circuit Applies Safe Harbor to Imported Medical Device Samples
27 Mar 2024, 10:56 am by Matt Kurnick
The 2019 decision Amgen Inc. v. [read post]
PharmaPatents - https://www.foley.com/en/insights/blogs/pharmapatents
Surely You Must be Kidding, PTO?!? “No, and Don’t Call Me Shirley!” – The Seemingly Slapstick (But Yet Unfunny) World of Recent Patent Term Extension Decisions (PART 3 . . . and PART 3½)
13 Mar 2024, 7:24 pm by Kurt R. Karst
The PTE application states “[u]nder the terms of the AMENDED AND RESTATED DEVELOPMENT AND COMMERCIALIZATION LICENSE AGREEMENT between Pfizer Inc. and OPKO Ireland Ltd. [read post]
FDA Law Blog - https://www.thefdalawblog.com/
Celanese v. ITC: Can a Secret Manufacturing Process Be Patented After Sale of the Resulting Product?
4 Mar 2024, 9:45 am by Dennis Crouch
Teva Pharmaceuticals USA, Inc. held that in the AIA, Congress did not change the meaning of “on sale” from the pre-AIA statute. [read post]
Patently-O - https://patentlyo.com
Trademark Use in the U.S.
29 Feb 2024, 5:54 am by Marc Misthal
Hi-Tech Pharmaceuticals, Inc. sought to register EXPERIMENTAL AND APPLIED SCIENCES as a trademark for use in connection with dietary and nutritional supplements. [read post]
New Jersey Property Management Blog - https://www.offitkurman.com/resources/legal-blog/
The Taxman, Technology Litigation and Cavalier Settlement Structures
20 Feb 2024, 4:56 pm by Brian Clark and Joshua Smeltzer
In Acqis Technology, Inc. v. [read post]
Dollars & Sense - https://dollarsandsense.grayreed.com/
Obviousness: Is a Reasonable Expectation of Success Sufficient
19 Feb 2024, 12:55 pm by Dennis Crouch
Altoona Publix Theatres, Inc. v. [read post]
Patently-O - https://patentlyo.com
Overruling Chevron and FDA Decision-Making, by Nikhil Chaudhry, Dr. Reshma Ramachandran, and Dr. Joseph Ross
9 Feb 2024, 11:08 am by Guest Author
” Similarly, as show in the Mylan Laby’s, Inc. v. [read post]
Notice & Comment - https://www.yalejreg.com/nc/
Are Non-Traded REITs a Safe Bet?
25 Jan 2024, 6:06 pm by The White Law Group
  EQT Exeter: EQT Exeter Real Estate Income Trust  Investment Focus: Stabilized, income-oriented U.S. commercial real estate, primarily targeting supply chain industrial properties and offices leased to research and development tenants in healthcare, biotech, and pharmaceuticals. [read post]
The White Law Group's Securities Fraud Blog - http://www.whitesecuritieslaw.com/securities-fraud/blog/
Health Care Provider Risks When Ordering and Billing Chelation Therapy Services
25 Jan 2024, 5:31 am by Ashley Morgan
As the warning stated, in part: "There are no FDA-approved OTC chelation products. [read post]
Liles Parker PLLC Blog - http://www.lilesparker.com
Wachtell Lipton Discusses U.S. M&A Antitrust Enforcement for  2023 and the Year Ahead
21 Jan 2024, 9:01 pm by renholding
  In Seven & i Holdings Co., Ltd. and 7-Eleven, Inc. [read post]
The CLS Blue Sky Blog - https://clsbluesky.law.columbia.edu/
Would I FIE to You? FDA’s First Interchangeable Exclusivity Determination Results in Expiration
11 Jan 2024, 12:03 am by Kurt R. Karst
The FIE determination released in fall 2023 involves the Reference Product AbbVie’s Humira (adalimumab) and two interchangeable biosimilars—first approved is Cyltezo (adalimumab-adbm), filed by Boehringer Ingelheim Pharmaceuticals, Inc, which was followed by Abrilada (adalimumab-afzb), filed by Pfizer. [read post]
FDA Law Blog - https://www.thefdalawblog.com/
The Top Ten Stories in D&O of 2023
2 Jan 2024, 12:56 pm by Kevin LaCroix
Thus, by my tally there were 25 securities class action lawsuits filed against companies in the 283 SIC Code Industry Group (Drugs), including 17 in the 2834 SIC Code category (Pharmaceutical Preparations). [read post]
The D & O Diary - http://www.dandodiary.com/
Top IP Developments of 2023
31 Dec 2023, 4:29 pm by Thomas James
Major developments occurred in every area. [read post]
Cokato Copyright Attorney - https://www.thomasbjames.com
TTAB Posts January 2024 Hearing Schedule
29 Dec 2023, 3:26 am
"] January 23, 2024 - 1 PM: Sage Therapeutics, Inc. v. [read post]
The TTABlog - http://thettablog.blogspot.com/
The SCOTUS Antibody Ruling Has an Uncertain Impact for Drug Makers and Patients
20 Dec 2023, 5:00 am by Timothy Bonis
Monoclonal Antibodies Inc., 1985) protected large genus claims. [read post]
Bill of Health - https://blog.petrieflom.law.harvard.edu/